{"database": "lobbying", "table": "lobbying_activities", "rows": [[3801620, "f85b5557-dc26-4b1e-b877-0e174629fd7d", "Q1", "THE WASHINGTON TAX & PUBLIC POLICY GROUP", 294930, "ALLIANCE FOR BIOPHARMACEUTICAL COMPETITIVENESS AND INNOVATION", 2026, "first_quarter", "TAX", "Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income and the potential impacts on financial reporting and on the tax base of the U.S. and its Territories. Issues related to the taxation of intellectual property income. Issues related to IRC sections 11, 41 and 174, 55, 56A, and 59, 59A, 163(j), 250, 951A.", "HOUSE OF REPRESENTATIVES,SENATE", 500000, null, 0, 0, "2026-04-01T12:41:01-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["3801620"], "units": {}, "query_ms": 0.5111100617796183, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}